Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590178 | 0.85 | TSHR (0.31) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL34317 | 0.79 | CA1 (0.36) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL516304 | 0.79 | CA1 (0.36) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL8800537 | 0.78 | TSHR (0.32) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL5588806 | 0.78 | IMPDH2 (0.33) | — | |
| SCHEMBL5586774 | 0.78 | IMPDH2 (0.33) | — | |
| SCHEMBL5697079 | 0.77 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL18697361 | 0.77 | CA1 (0.35) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL16814869 | 0.77 | CA1 (0.35) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL570928 | 0.77 | PREP (0.39) | CA1CA2CA9TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619038-A2 | ANIONICALLY FUNCTIONALIZED POLYPEPTIDES, AND METHODS OF MAKING SAME AND USES THEREOF | Cornell University (US) | 2025-09-24 | — | — | EP | claimed |
| CN-119674227-A | Quick-charging electrolyte, lithium ion battery, and preparation method and application of quick-charging electrolyte and lithium ion battery | 中国科学院大连化学物理研究所 | 2025-03-21 | — | — | CN | claimed |
| WO-2024107780-A2 | ANIONICALLY FUNCTIONALIZED POLYPEPTIDES, AND METHODS OF MAKING SAME AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-05-23 | — | — | WO | claimed |
| CN-116655585-A | Poly (epsilon-caprolactone-epsilon-caprolactam) with controllable main chain sequence and preparation method and application thereof | 中国科学院化学研究所 | 2023-08-29 | — | — | CN | claimed |
| CN-116159445-A | Polyamide composite membrane and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| US-10611792-B2 | Functionalized bile acids for therapeutic and material applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2020-04-07 | — | — | US | claimed |
| US-20190211051-A1 | FUNCTIONALIZED BILE ACIDS FOR THERAPEUTIC AND MATERIAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2019-07-11 | — | — | US | claimed |
| US-20190153019-A1 | FUNCTIONALIZED BILE ACIDS FOR THERAPEUTIC AND MATERIAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2019-05-23 | — | — | US | claimed |
| US-10294265-B1 | Functionalized bile acids for therapeutic and material applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2019-05-21 | — | — | US | claimed |
| EP-2802556-B1 | LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2017-01-04 | — | — | EP | claimed |
| EP-2802556-A1 | LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2014-11-19 | — | — | EP | claimed |
| WO-2013104346-A1 | LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2013-07-18 | — | — | WO | claimed |
| US-8410290-B2 | Cyclic carbonyl compounds with pendant carbonate groups, preparations thereof, and polymers therefrom | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-04-02 | — | — | US | claimed |
| US-8389746-B2 | Cyclic carbonyl compounds with pendant carbonate groups, preparations thereof, and polymers therefrom | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-03-05 | — | — | US | claimed |
| US-20120252983-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | CENTRAL GLASS CO., LTD. (JP) | 2012-10-04 | — | — | US | claimed |
| US-20120245304-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | CENTRAL GLASS CO., LTD. (JP) | 2012-09-27 | — | — | US | claimed |
| US-8207351-B2 | Cyclic carbonyl compounds with pendant carbonate groups, preparations thereof, and polymers therefrom | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-06-26 | — | — | US | claimed |
| WO-2011135046-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT PENTAFLUOROPHENYL CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-11-03 | — | — | WO | claimed |
| US-20110269917-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | CENTRAL GLASS CO., LTD. (JP) | 2011-11-03 | — | — | US | claimed |
| EP-1498978-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | UBE INDUSTRIES (JP) | 2010-09-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611792-B2 | Functionalized bile acids for therapeutic and material applications | NR1H4, SLC10A2, GPBAR1 | CA1 150/4885CA2 1584/4885CA9 63/4885 |
| US-20120252983-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | NOTUM, PFAS, PCNA | CA1 133/4885CA2 90/4885CA9 303/4885 |
| US-20190211051-A1 | FUNCTIONALIZED BILE ACIDS FOR THERAPEUTIC AND MATERIAL APPLICATIONS | NR1H4, SLC10A2, GPBAR1 | CA1 150/4885CA2 1584/4885CA9 63/4885 |
| US-20190153019-A1 | FUNCTIONALIZED BILE ACIDS FOR THERAPEUTIC AND MATERIAL APPLICATIONS | NR1H4, SLC10A2, GPBAR1 | CA1 150/4885CA2 1584/4885CA9 63/4885 |
| US-10294265-B1 | Functionalized bile acids for therapeutic and material applications | NR1H4, SLC10A2, GPBAR1 | CA1 150/4885CA2 1584/4885CA9 63/4885 |
| US-20110269917-A1 | CYCLIC CARBONYL COMPOUNDS WITH PENDANT CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM | NOTUM, PFAS, PCNA | CA1 133/4885CA2 90/4885CA9 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.